These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
104 related articles for article (PubMed ID: 22826825)
81. Hormone therapy and brain structure in postmenopausal women. Molano JR Neurology; 2016 Aug; 87(9):e100-2. PubMed ID: 27572433 [No Abstract] [Full Text] [Related]
82. Do the cardiovascular disease risks and benefits of oral versus transdermal estrogen therapy differ between perimenopausal and postmenopausal women? Clarkson TB; Karas RH Menopause; 2007; 14(6):963-7. PubMed ID: 17909452 [No Abstract] [Full Text] [Related]
83. Addendum: Transdermal estrogen (Med Lett Drugs Ther 2012;54:41). Med Lett Drugs Ther; 2012 Jul; 54(1394):56. PubMed ID: 22826825 [No Abstract] [Full Text] [Related]
84. Should transdermal rather than oral estrogens be used in menopausal hormone therapy? A review. Fournier A Menopause Int; 2010 Mar; 16(1):23-32. PubMed ID: 20424283 [TBL] [Abstract][Full Text] [Related]
85. Alternatives to oral estrogen replacement. Transdermal patches, percutaneous gels, vaginal creams and rings, implants, other methods of delivery. Baker VL Obstet Gynecol Clin North Am; 1994 Jun; 21(2):271-97. PubMed ID: 7936545 [TBL] [Abstract][Full Text] [Related]
86. The pharmacokinetics and efficacy of different estrogens are not equivalent. Ansbacher R Am J Obstet Gynecol; 2001 Feb; 184(3):255-63. PubMed ID: 11228470 [TBL] [Abstract][Full Text] [Related]
87. Risk of venous thrombosis with oral versus transdermal estrogen therapy among postmenopausal women. Olié V; Canonico M; Scarabin PY Curr Opin Hematol; 2010 Sep; 17(5):457-63. PubMed ID: 20601871 [TBL] [Abstract][Full Text] [Related]
89. Vaginal estrogen in the treatment of genitourinary syndrome of menopause and risk of endometrial cancer: an assessment of recent studies provides reassurance. Pinkerton JV; Kaunitz AM; Manson JE Menopause; 2017 Dec; 24(12):1329-1332. PubMed ID: 29040220 [No Abstract] [Full Text] [Related]
90. Estrogen replacement and migraine. MacGregor EA Maturitas; 2009 May; 63(1):51-5. PubMed ID: 19375252 [TBL] [Abstract][Full Text] [Related]
92. [Hormone therapy and risk for venous thromboembolism in postmenopausal women]. Lacut K; Oger E Rev Prat; 2005 Feb; 55(4):389-92. PubMed ID: 15828617 [TBL] [Abstract][Full Text] [Related]
93. Relative value of transdermal and oral estrogen therapy in various clinical situations. Lufkin EG; Ory SJ Mayo Clin Proc; 1994 Feb; 69(2):131-5. PubMed ID: 8309263 [TBL] [Abstract][Full Text] [Related]
96. Exogenous and endogenous estrogens: an appreciation of biological complexity. Kronenberg F; Hughes C Menopause; 1999; 6(1):4-6. PubMed ID: 10100173 [No Abstract] [Full Text] [Related]
97. The menopause: benefits and risks of hormone replacement therapy. Gambrell RD Compr Ther; 1994; 20(10):580-5. PubMed ID: 7859441 [No Abstract] [Full Text] [Related]
98. Low-dose estrogen therapy for menopausal women: a review of efficacy and safety. Crandall C J Womens Health (Larchmt); 2003 Oct; 12(8):723-47. PubMed ID: 14588124 [TBL] [Abstract][Full Text] [Related]
99. Transdermal estrogen replacement therapy. An overview of today's issues. Alexander IM Adv Nurse Pract; 2000 Aug; 8(8):60-3. PubMed ID: 11761525 [No Abstract] [Full Text] [Related]